VX-809: Clinical Trials

4 trials of VX-809, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed. 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 34Completed 4

Follow VX-809: new trials by email Literature Review of VX-809 trials Research Report on VX-809

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
LUM, IVA - Cystic Fibrosis
Phase 3CompletedVertex Pharmaceuticals Incorporated612018-09-072023-01-06
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
VX-809, Placebo, VX-770 - Cystic Fibrosis
Phase 3CompletedVertex Pharmaceuticals Incorporated2062015-07-012017-10-23
Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease
Lumacaftor, Ivacaftor - Cystic Fibrosis, Advanced Lung Disease
Phase 3CompletedVertex Pharmaceuticals Incorporated462015-03-012017-12-06
Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Lumacaftor, Ivacaftor - Cystic Fibrosis
Phase 3CompletedVertex Pharmaceuticals Incorporated622013-07-012017-06-20

Conditions studied

Cystic Fibrosis (4)

Sponsors

Vertex Pharmaceuticals Incorporated (4)

Countries

United States (4)  ·  Canada (3)  ·  Australia (1)  ·  Belgium (1)  ·  Denmark (1)  ·  France (1)  ·  Germany (1)  ·  Sweden (1)  ·  United Kingdom (1)

Results publications

PMID 33331662, PMID 37983082, PMID 27805836, PMID 28606620, PMID 29126871, PMID 35771568

NIH funding

2017 (1)